TY - JOUR
T1 - Japanese nationwide surveillance in 2011 of antibacterial susceptibility patterns of clinical isolates from complicated urinary tract infection cases
AU - Ishikawa, Kiyohito
AU - Hamasuna, Ryoichi
AU - Uehara, Shinya
AU - Yasuda, Mitsuru
AU - Yamamoto, Shingo
AU - Hayami, Hiroshi
AU - Takahashi, Satoshi
AU - Matsumoto, Tetsuro
AU - Minamitani, Shinichi
AU - Kadota, Jun ichi
AU - Iwata, Satoshi
AU - Kaku, Mitsuo
AU - Watanabe, Akira
AU - Sunakawa, Keisuke
AU - Sato, Junko
AU - Hanaki, Hideaki
AU - Tsukamoto, Taiji
AU - Kiyota, Hiroshi
AU - Egawa, Shin
AU - Deguchi, Takashi
AU - Matsumoto, Minori
AU - Tanaka, Kazushi
AU - Arakawa, Soichi
AU - Fujisawa, Masato
AU - Kumon, Hiromi
AU - Kobayashi, Kanao
AU - Matsubara, Akio
AU - Wakeda, Hironobu
AU - Amemoto, Yoshinosuke
AU - Onodera, Shoichi
AU - Goto, Hirokazu
AU - Komeda, Hisao
AU - Yamashita, Masuo
AU - Takenaka, Tadasu
AU - Fujimoto, Yoshinori
AU - Tsugawa, Masaya
AU - Takahashi, Yoshito
AU - Maeda, Hiroshi
AU - Onishi, Hiroyuki
AU - Ishitoya, Satoshi
AU - Nishimura, Kazuo
AU - Mitsumori, Kenji
AU - Ito, Toru
AU - Togo, Yoshikazu
AU - Nakamura, Ichiro
AU - Ito, Noriyuki
AU - Kanamaru, Sojun
AU - Hirose, Takaoki
AU - Muranaka, Takashi
AU - Yamada, Daisuke
AU - Ishihara, Satoshi
AU - Oka, Hiroya
AU - Inatomi, Hisato
AU - Matsui, Takashi
AU - Kobuke, Makoto
AU - Kunishima, Yasuharu
AU - Kimura, Takahiro
AU - Ichikawa, Takaharu
AU - Kagara, Ichiro
AU - Matsukawa, Masanori
AU - Takahashi, Koichi
AU - Mita, Koji
AU - Kato, Masao
AU - Okumura, Kazuhiro
AU - Kawanishi, Hiroaki
AU - Hashimura, Takayuki
AU - Aoyama, Teruyoshi
AU - Shigeta, Masanobu
AU - Koda, Shuntaro
AU - Taguchi, Keisuke
AU - Matsuda, Yohei
N1 - Funding Information:
Mitsuru Yasuda has received donation from Astellas Pharma Inc. Jun-ichi Kadota has received speaker’s honorarium from Taisho Toyama Pharmaceutical Co., Ltd., Pfizer Japan Inc., MSD K.K., Kyorin Pharmaceutical Co.,Ltd., Daiichi Sankyo Co., Ltd., Glaxo SmithKline K.K., payments for a manuscript drafting and editing from Nankodo Co., Ltd. and donation from Astellas Pharma Inc. Satoshi Iwata has received speaker's honorarium from Astellas Pharma Inc., Pfizer Japan Inc., Taisho Toyama Pharmaceutical Co., Ltd., MSD K.K., Meiji Seika Pharma Co., Ltd., Daiichi Sankyo Co., Ltd. and Japan Vaccine Co., Ltd., donation from Taisho Toyama Pharmaceutical Co., Ltd. and supported, in part, by a fund from Nikon Corporation. Mitsuo Kaku has received speaker's honorarium from Taisho Toyama Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Pfizer Japan Inc. and Sumitomo Dainippon Pharma Co., Ltd. and donation from Astellas Pharma Inc. Akira Watanabe has received speaker's honorarium from MSD K.K., Glaxo SmithKline K.K., Shionogi & Co., Ltd., Daiichi Sankyo Co.,Ltd., Taisho Toyama Pharmaceutical Co., Ltd. and Pfizer Japan Inc.; grant support from Kyorin Pharmaceutical Co., Ltd., Shionogi & Co.,Ltd., Taisho Pharmaceutical Co.,Ltd., Toyama Chemical Co., Ltd., Daiichi Sankyo Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Taiho Pharmaceutical Co.,Ltd. and Meiji Seika Pharma Co., Ltd. Keisuke Sunakawa has received speaker's honorarium from Taisho Toyama Pharmaceutical Co., Ltd., Toyama Chemical Co., Ltd. and Meiji Seika Pharma Co., Ltd. Hideaki Hanaki is a member of a laboratory endowed chair from Kohjin Bio Co., Ltd. Taiji Tsukamoto has received speaker's honorarium from Astellas Pharma Inc., and payments for a manuscript drafting and editing from RichHill Medical Inc. Shin Egawa has received donation from Takeda Pharmaceutical Co., Ltd., Astellas Pharma Inc., Asahi Kasei Corp. and Euro Meditech Co., Ltd. Takashi Deguchi has received donation from Astellas Pharma Inc. Soichi Arakawa has received speaker's honorarium from Taisho Toyama Pharmaceutical Co., Ltd.
Publisher Copyright:
© 2015.
PY - 2015/9/1
Y1 - 2015/9/1
N2 - To investigate antimicrobial susceptibility patterns of various bacterial pathogens isolated from complicated urinary tract infection (UTI) cases, the Japanese Society of Chemotherapy, the Japanese Association of Infectious Disease, and the Japanese Society of Clinical Microbiology conducted the second nationwide surveillance from January to September 2011. With the cooperation of 42 medical institutions throughout Japan, 1036 strains belonging to 8 clinically relevant bacterial species were collected.Among methicillin-resistant Staphylococcus aureus (MRSA) strain, the vancomycin (VCM) MIC for 5.5% (3/55) of the strains was 2 μg/mL. Ampicillin, VCM, and linezolid were relatively active against 209 Enterococcus faecalis strains. The proportion of fluoroquinolone (FQ)-resistant strains was >20%.The MIC90 of FQs against the 382 Escherichia coli strains was 2-64 mg/L and the proportion resistant to FQs was approximately 30%. However, susceptibility of E. coli to sitafloxacin was still high (MIC90 = 2 mg/L). Fifty-eight (15.2%) of 382 E. coli, 6 (4.5%) of 132 Klebsiella pneumoniae, 1 (2.4%) of 41 Klebsiella oxytoca and 4 (6.8%) of 59 Proteus mirabilis strains were suspected of producing extended-spectrum beta-lactamase.Of 93 Pseudomonas aeruginosa strains, the proportions resistant to imipenem, amikacin, and ciprofloxacin were 21.5%, 4.3%, and 20.4%, respectively. Four strains (4.3%) were found to be multidrug-resistant.In complicated UTI cases, all of MRSA and E. faecalis were susceptible to all anti-MRSA agents. Sitafloxacin was active against other FQ-resistant E. coli strains. The isolation of extended-spectrum beta-lactamase-producing and multidrug-resistant strains increased.
AB - To investigate antimicrobial susceptibility patterns of various bacterial pathogens isolated from complicated urinary tract infection (UTI) cases, the Japanese Society of Chemotherapy, the Japanese Association of Infectious Disease, and the Japanese Society of Clinical Microbiology conducted the second nationwide surveillance from January to September 2011. With the cooperation of 42 medical institutions throughout Japan, 1036 strains belonging to 8 clinically relevant bacterial species were collected.Among methicillin-resistant Staphylococcus aureus (MRSA) strain, the vancomycin (VCM) MIC for 5.5% (3/55) of the strains was 2 μg/mL. Ampicillin, VCM, and linezolid were relatively active against 209 Enterococcus faecalis strains. The proportion of fluoroquinolone (FQ)-resistant strains was >20%.The MIC90 of FQs against the 382 Escherichia coli strains was 2-64 mg/L and the proportion resistant to FQs was approximately 30%. However, susceptibility of E. coli to sitafloxacin was still high (MIC90 = 2 mg/L). Fifty-eight (15.2%) of 382 E. coli, 6 (4.5%) of 132 Klebsiella pneumoniae, 1 (2.4%) of 41 Klebsiella oxytoca and 4 (6.8%) of 59 Proteus mirabilis strains were suspected of producing extended-spectrum beta-lactamase.Of 93 Pseudomonas aeruginosa strains, the proportions resistant to imipenem, amikacin, and ciprofloxacin were 21.5%, 4.3%, and 20.4%, respectively. Four strains (4.3%) were found to be multidrug-resistant.In complicated UTI cases, all of MRSA and E. faecalis were susceptible to all anti-MRSA agents. Sitafloxacin was active against other FQ-resistant E. coli strains. The isolation of extended-spectrum beta-lactamase-producing and multidrug-resistant strains increased.
KW - Complicated urinary tract infection
KW - Surveillance
KW - Susceptibility
UR - http://www.scopus.com/inward/record.url?scp=84939573549&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939573549&partnerID=8YFLogxK
U2 - 10.1016/j.jiac.2015.05.014
DO - 10.1016/j.jiac.2015.05.014
M3 - Article
C2 - 26166322
AN - SCOPUS:84939573549
SN - 1341-321X
VL - 21
SP - 623
EP - 633
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
IS - 9
ER -